Equillium, Inc. Gains 26.86%

Equillium, Inc. (EQ:NASDAQ) soared at $6.14, representing a gain of 26.9%. On Fri, Aug 20, 2021, EQ:NASDAQ touched a New 2-Week Low of $4.84. The stock got featured on our News Catalysts scanner on Wed, Aug 11, 2021 at 05:26 PM in the 'BIOTECH' category. From Fri, Aug 06, 2021, the stock recorded 30.00% Up Days and 27.27% Green Days

About Equillium, Inc. (EQ:NASDAQ)

Equillium Inc is a biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is EQ001, which is a clinical stage first-in-class monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. CD6 plays a central role in effector T cell activity, which drives a number of immuno-inflammatory diseases such as graft versus host disease, asthma, uveitis, colitis, lupus and multiple sclerosis.